Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Introduction: A recently emerging respiratory disease named coronavirus disease 2019 (COVID-19) has quickly spread across the world. This disease is initiated by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and uncontrolled cytokine storm, but it remains unknown as to whether a robust antibody response is related to clinical deterioration and poor outcome in COVID-19 patients. Methods: Anti-SARS-CoV-2 IgG and IgM antibodies were determined by chemiluminescence analysis (CLIA) in COVID-19 patients at a single center in Wuhan. Median IgG and IgM levels in acute and convalescent-phase sera (within 35 days) for all included patients were calculated and compared between severe and nonsevere patients. Immune response phenotyping based on the late IgG levels and neutrophil-to-lymphocyte ratio (NLR) was characterized to stratified patients into different disease severities and outcomes. Results: A total of 222 patients were included in this study. IgG was first detected on day 4 of illness, and its peak levels occurred in the fourth week. Severe cases were more frequently found in patients with high IgG levels, compared to those with low IgG levels (51.8% versus 32.3%; p=0.008). Severity rates for patients with NLRhiIgGhi, NLRhiIgGlo, NLRloIgGhi, and NLRloIgGlo phenotype were 72.3%, 48.5%, 33.3%, and 15.6%, respectively (p<0.0001). Furthermore, severe patients with NLRhiIgGhi, NLRhiIgGlo had higher proinflammatory cytokines levels including IL-2, IL-6 and IL-10, and decreased CD4+ T cell count compared to those with NLRloIgGlo phenotype (p<0.05). Recovery rates for severe patients with NLRhiIgGhi, NLRhiIgGlo, NLRloIgGhi, and NLRloIgGlo phenotype were 58.8% (20/34), 68.8% (11/16), 80.0% (4/5), and 100% (12/12), respectively (p=0.0592). Dead cases only occurred in NLRhiIgGhi and NLRhiIgGlo phenotypes. Conclusions: COVID-19 severity is associated with increased IgG response, and an immune response phenotyping based on the late IgG response and NLR could act as a simple complementary tool to discriminate between severe and nonsevere COVID-19 patients, and further predict their clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationThe third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 1×
“Since December 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has quickly spread across the world (Wu et al., 2020).”
BackgroundEarly goal-directed therapy in the treatment of severe sepsis and septic shock
Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., & Tomlanovich, M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010307 · Cited by 10,743 · cited 2×
“In fact, proinflammatory and an opposing anti-inflammatory response occur concomitantly in virus infection as well as sepsis (Rivers et al., 2001; Zhang C. et al., 2020).”
BackgroundPathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 1×
“Following SARS-CoV-2 infection, a high viral load and overexuberant host immune response involving innate and acquired immunity, simultaneously contributes to the pathogenesis of COVID-19 and organ injury (Huang et al., 2020; Wang et al., 2020; Xu et al., 2020).”
BackgroundInfluentialZhang, C., Wu, Z., Li, J.-W., Zhao, H., & Wang, G.-Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105954 · Cited by 1,758
Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102763 · Cited by 1,702
Self-citationLiu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C., Zhang, M., Tan, J., Xu, Y., Song, R., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02374-0 · Cited by 1,082
Research works printed but not linked: 1
- Zhang, 2020, Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19, medRxiv, 10.1101/2020.03.12.20035048 · DOI
Cited by
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
COVID-19: immunopathology and its implications for therapy
Cao, X. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0308-3 · Cited by 1,609
Neutrophil extracellular traps in COVID-19
Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J. A., Blair, C. N., Weber, A., Barnes, B. J., Egeblad, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138999 · Cited by 1,582
A single-cell atlas of the peripheral immune response in patients with severe COVID-19
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martínez-Colón, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0944-y · Cited by 1,493
Aging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
COVID-19: immunopathogenesis and Immunotherapeutics
Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., Chen, Y., & Zhang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00243-2 · Cited by 912
Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V., Mastroiani, F., Turtle, C. J., Harhay, M. O., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30404-5 · Cited by 855
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
Soy, M., Keser, G., Atagündüz, P., Tabak, F., Atagündüz, I., & Kayhan, S. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05190-5 · Cited by 811
Wang, J., Jiang, M., Chen, X., & Montaner, L. J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3covr0520-272r · Cited by 741
Self-citationCOVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections
Machhi, J., Herskovitz, J., Senan, A. M., Dutta, D., Nath, B., Oleynikov, M. D., Blomberg, W. R., Meigs, D. D., Hasan, M., Patel, M., et al. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09944-5 · Cited by 617
Catanzaro, M., Fagiani, F., Racchi, M., Corsini, E., Govoni, S., & Lanni, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0191-1 · Cited by 605
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
A systematic review of SARS-CoV-2 vaccine candidates
Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00352-y · Cited by 545
The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review
Oran, D. P., & Topol, E. J. (2021) · Annals of Internal Medicine · doi:10.7326/m20-6976 · Cited by 533
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Bange, E. M., Han, N. A., Wileyto, P., Kim, J. Y., Gouma, S., Robinson, J., Greenplate, A. R., Hwee, M. A., Porterfield, F., Owoyemi, O., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01386-7 · Cited by 519
Serum IgA, IgM, and IgG responses in COVID-19
Ma, H., Zeng, W., He, H., Zhao, D., Jiang, D., Zhou, P., Cheng, L., Li, Y., Ma, X., & Jin, T. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0474-z · Cited by 511
Evans, P. C., Rainger, G. E., Mason, J. C., Guzik, T. J., Osto, E., Stamataki, Z., Neil, D., Hoefer, I. E., Fragiadaki, M., Waltenberger, J., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa230 · Cited by 437
Klein, S. L., Pekosz, A., Park, H.-S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K., Kumar, S., Naik, H. M., Betenbaugh, M. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142004 · Cited by 432
Molecular Diagnosis of COVID-19: Challenges and Research Needs
Feng, W., Newbigging, A. M., Le, C., Pang, B., Peng, H., Cao, Y., Wu, J., Abbas, G., Song, J., Wang, D.-B., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02060 · Cited by 389
Antibody response to SARS-CoV-2 infection in humans: A systematic review
Post, N., Eddy, D., Huntley, C., van Schalkwyk, M. C. I., Shrotri, M., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0244126 · Cited by 374
Serology testing in the COVID-19 pandemic response
Peeling, R. W., Wedderburn, C. J., Garcia, P. J., Boeras, D., Fongwen, N., Nkengasong, J., Sall, A., Tanuri, A., & Heymann, D. L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30517-x · Cited by 360
Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., & Wang, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa721 · Cited by 359
T cell response to SARS-CoV-2 infection in humans: A systematic review
Shrotri, M., van Schalkwyk, M. C. I., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0245532 · Cited by 350
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00653-w · Cited by 339
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
Perera, R. A., Mok, C. K., Tsang, O. T., Lv, H., Ko, R. L., Wu, N. C., Yuan, M., Leung, W. S., Chan, J. M., Chik, T. S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.16.2000421 · Cited by 322
Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis
Kontou, P. I., Braliou, G. G., Dimou, N. L., Nikolopoulos, G., & Bagos, P. G. (2020) · Diagnostics · doi:10.3390/diagnostics10050319 · Cited by 288
Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2
Salamanna, F., Maglio, M., Landini, M. P., & Fini, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.594495 · Cited by 281
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00103-x · Cited by 278
Neutrophil extracellular traps and thrombosis in COVID-19
Zuo, Y., Zuo, M., Yalavarthi, S., Gockman, K., Madison, J. A., Shi, H., Woodard, W., Lezak, S. P., Lugogo, N. L., Knight, J. S., et al. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02324-z · Cited by 267
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control
Lee, C. Y.-P., Lin, R. T. P., Renia, L., & Ng, L. F. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00879 · Cited by 260
Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19
Chan, A. S., & Rout, A. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4240 · Cited by 233
Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis
Karimi, A., Shobeiri, P., Kulasinghe, A., & Rezaei, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741061 · Cited by 171
Jiang, C., Wang, Y., Hu, M., Wen, L., Wen, C., Wang, Y., Zhu, W., Tai, S., Jiang, Z., Xiao, K., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1182 · Cited by 72
Criscuolo, E., Diotti, R. A., Strollo, M., Rolla, S., Ambrosi, A., Locatelli, M., Burioni, R., Mancini, N., Clementi, M., & Clementi, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26605 · Cited by 62
Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes
Dobosh, B., Zandi, K., Giraldo, D. M., Goh, S. L., Musall, K., Aldeco, M., LeCher, J., Giacalone, V. D., Yang, J., Eddins, D. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110945 · Cited by 19
“Meanwhile, neutrophil counts and the neutrophil-to-lymphocyte ratio are elevated in the blood of patients with severe COVID-19 (Qin et al., 2020; Zhang et al., 2020).”
Metadata
- Authors
- Zhang, B., Zhou, X., Zhu, C., Song, Y., Feng, F., Qiu, Y., Feng, J., Jia, Q., Song, Q., Zhu, B., & Wang, J.
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2020-07-03
- Volume
- 7
- Pages
- 157-157
- ISSN
- 2296-889X (ISSN-L)
- OpenAlex
- W3045525085
- Cited by
- 528
- References
- 18
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.